Landrum Brewer Shettles is remembered as an important contributor to early in vitro fertilization research in the United States as well as a prolific author on the subject of choosing a child's sex before conception. Shettles was born in Pontotoc County, Mississippi on 21 November 1909 to Sue Mounce and Brazil Manly. Shettles trained and worked as a gynecologist at Columbia University Presbyterian Medical Center, after receiving his MD in 1943 from Johns Hopkins University. While working at Columbia, Shettles conducted experiments dealing with egg fertilization and in vitro fertilization. From this work, Shettles published Ovum Humanum, a book containing detailed photographs of human eggs in development. Despite professional eccentricities and social ineptitude that, at times, hindered his work with colleagues, Shettles is considered a pioneer of in vitro fertilization technology as well as a major contributor to fertilization and embryonic research.

Leuprolide acetate, or leuprorelin, is a manufactured drug that has been prescribed as a treatment for endometriosis, a medical condition in which body tissue that typically lines the uterus grows outside of the uterus, since 1989. Leuprorelin is a modified version of a gonadotropin-releasing hormone, a type of hormone that helps regulate the female menstrual cycle. The drug inhibits the production of estrogen, a female sex hormone that enables endometrial gland growth. After two weeks of injections, leuprorelin stops the production of estrogen, and without estrogen, endometrial glands become inactive. That decreases the growth of uterine tissue outside of the uterus, which helps decrease the pain associated with endometriosis. Although physicians commonly prescribe leuprorelin as of 2019, women with endometriosis have reported adverse side effects and health complications.

Robert Geoffrey Edwards, a British developmental biologist at University of Cambridge, began exploring human in vitro fertilization (IVF) as a way to treat infertility in 1960. After successfully overcoming the problem of making mammalian oocytes mature in vitro in 1965, Edwards began to experiment with fertilizing matured eggs in vitro. Collaborating with other researchers, Edwards eventually fertilized a human egg in vitro in 1969. This was a huge step towards establishing human IVF as a viable fertility treatment. During the four years in which Edwards experimented with IVF, he experienced many setbacks. These failures in fertilizing oocytes in vitro, however, contributed to the understanding of how fertilization did or did not happen, which was sometimes different from established dogmas. Edwards also collaborated with gynecologist and surgeon Patrick Christopher Steptoe to study sperm capacitation, which became the overture that heralded a series of successes for the team, culminating in the generation of the first test-tube baby Louise Joy Brown in 1978.

The court treated frozen embryos possessed by an in vitro fertilization clinic as property owned by the parents and held under a bailment contract by the clinic. As such, the contract between the parties controlled disposition of the embryos but when the contract ended, control of the embryos reverted back to the parents. This decision had little effect on subsequent embryo cases because the circumstances were so unusual. Neither party contended the embryos had any rights.

The implication of the court's decision was that Thomas Doolan's identity or personhood existed at the embryo stage in vitro, thus the fact that he was born with cystic fibrosis was not attributable to the decision of the in vitro fertilization providers to implant one embryo instead of another. The other unused embryo may not have carried the cystic fibrosis genes, but that other embryo was not Thomas Doolan. The decision in Doolan has not been publicly tested in other jurisdictions.

In a dispute over frozen embryos during a divorce case, the court decided the wife's fundamental right to not procreate mandated destruction of the pre-embryos in light of the husband's continuing ability to procreate with a different partner. The court also said embryo disposition agreements used by in vitro fertilization clinics were generally enforceable subject to either spouse's right to change his or her mind prior to use of the pre-embryos.

Pursuant to an express provision of the embryo disposition contract they both signed, a husband and wife had to petition the court for instructions because they could not reach an agreement about what to do with frozen embryos when they divorced. The trial court awarded the pre-embryos to the husband and the Court of Appeals affirmed this decision. However, the Washington Supreme Court ruled that the pre-embryos should be thawed out and allowed to expire because the dispute had not been resolved within a five year time frame prescribed by the Cryopreservation Agreement. A dissenting opinion filed by one judge argued that the five year limit should not apply because of judicial delay in reaching a final decision.

In 1971, a group of researchers founded the Monash IVF Research Program with the mission to discover how in vitro fertilization, or IVF, techniques could become a treatment for infertility in both men and women. The program included researcher Carl Wood and colleagues John Leeton, Alex Lopata, Alan Trounson, and Ian Johnston at the Queen Victoria Medical Center and Royal Women’s Hospital in Melbourne, Australia. Since the program’s establishment in 1971, the Monash IVF Research Program has helped to develop and implement many IVF technologies still used in clinical practice as of 2020. Additionally, the program established some of the first successful IVF pregnancies and births. As of 2020, the Monash IVF Research Program is one of Australia’s leading fertility programs and has used their technologies to help provide IVF treatment to thousands of infertile men and women.

"MicroSort, developed in 1990 by the Genetics and IVF Institute, is a form of pre-conception sex selection technology for humans. Laboratories located around the world use MicroSort technology to help couples increase their chances of conceiving a child of their desired sex. MicroSort separates male sperm cells based on which sex chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same sex chromosome. The technology ultimately enables couples to choose the sex of their future child by choosing semen samples that predominately contain sperm with the X chromosome for a female or Y chromosome for a male. MicroSort technology is a sperm sorting technique that provides couples worldwide a means of pre-conception sex selection.

In the case York v. Jones (1989), the United States District Court for the Eastern District of Virginia was one of the first US courts to address a dispute over a cryopreserved preembryo. Steven York and Risa Adler-York (the Yorks), a married couple, provided their gametes to doctors who created the preembryo, which the court referred to as a pre-zygote, as part of an in vitro fertilization (IVF) program at the Howard and Georgeanna Jones Institute for Reproductive Medicine (Jones Institute) in Norfolk, Virginia. The couple sued when the doctors at the Jones Institute refused to release the preembryo to the Yorks for use at a different IVF clinic. The Virginia district court denied the Jones Institute's attempt to have the York v. Jones case dismissed, and instead upheld the Yorks' right to move forward with their lawsuit. The York v. Jones decision had important implications for future disputes over cryopreserved preembryos because it treated the Yorks' cryopreserved preembryo as legal property over which the Yorks retained decision-making authority.